CA
NZ
UK
AU
IND
US
Femasys Inc. secured $30 million through a private placement, providing the cash needed to fund its U.S. commercial strategy and move its FemBloc clinical program forward. The infusion improves liquidity, restoresNasdaqcompliance and gives investors a stronger financial foundation for upcoming growth initiatives.
The financial performance of HCW Biologics Inc. (NASDAQ: HCWB) in the second quarter showcased substantial progress, with revenues reaching $135,568, marking a dramatic increase from $6,550 reported in the corresponding quarter of the previous year. This impressive surge is a direct reflection of the …
HeartBeam, Inc. has entered into a significant At-The-Market Equity Offering Sales Agreement, enabling the company to sell an aggregate of up to $25 million of its common stock. This arrangement comes through an agreement signed with Titan Partners Securities LLC as the sales agent. …
Heron Therapeutics, Inc. (NASDAQ: HRTX) has taken a significant step by extending its Tax Benefit Preservation Plan's expiration date to August 14, 2029. This amendment modifies the prior expiration date, initially set for August 14, 2026. By pushing this deadline three more years into …
With this capital injection, Jasper aims to advance its promising pipeline of therapies focused on immune-mediated diseases that present significant patient needs. This financial backing is a important step for Jasper, paving the way for key development milestones in the upcoming quarters.
Lantern Pharma Inc. (NASDAQ: LTRN) announced a significant decrease in its second quarter loss from operations, which fell approximately 25% year over year to around $3.5 million. This positive trend reflects the company's ongoing focus on operational discipline and strategic management, demonstrating its capability …
Cue Biopharma, Inc. (NASDAQ: CUE) achieved $7.9 million in revenue for the second quarter ended June 30, 2026, marking a substantial rise from $3.0 million in the same period of the previous year. This revenue growth was attributed to revenue recognized from a milestone …
Dyadic International Inc. (NASDAQ: DYAI) has entered into a registered direct offering that will see an aggregate of 3,625,000 shares of its common stock sold at a price of $0.795 per share. This mechanism bypasses a traditional public offering, allowing the company to receive …
The revenue stream from LYMPHIR® highlights the strong momentum generated since its market debut, signaling that the product is resonating with oncology providers who are actively seeking novel therapeutic options. This uplift is directly linked to an expanding pipeline of cumulative orders, which has …
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) achieved revenue of $7.1 million from the sales of its immunotherapy product LYMPHIR during the first nine months of fiscal 2026. The financial results, released on August 14, reflect a continuing positive trajectory for the biopharmaceutical company's flagship product, …
Please wait processing your request...